Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

lined following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and InterMune's revenue is expected to continue to decline; (ii) risks related to regulation by the FDA and other agencies with respect to InterMune's communications with physicians concerning Actimmune for the treatment of IPF; (iii) reimbursement risks associated with third-party payors; (iv) risks related to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers to entry; (vi) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone may differ materially from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.

Actimmune(R) is a registered trademark of InterMune, Inc. Each other trademark, trade name or service mark appearing in this news release belongs to its holder.

Financial tables follow


'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Madison, NJ (PRWEB) April 16, 2015 ... recruited Dr. Joseph V. Gulfo to become the ... and Entrepreneurship. Simultaneously, FDU announced the kick-off of ... new program spearheaded by Dr. Gulfo, under the ... Silberman College of Business) and in collaboration with ...
(Date:4/16/2015)... Dana-Farber Cancer Institute and its ... Bioscience, Inc. today announced the successful completion of ... clinic ready, Next Generation Sequencing (NGS) assay for ... the first to demonstrate the successful sequencing of ... blinded plasma samples and highlights the ability to ...
(Date:4/16/2015)... Novato, California (PRWEB) April 16, 2015 ... financial incentives, MDF and joint planning management software for ... of its latest industry benchmark survey of channel vendor ... study explores:, How the top ... tactics; now and through the coming year. , ...
(Date:4/15/2015)... April 15, 2015  Richard Rubenstein, MD and Board Certified ... as one of South Florida,s Top ... physicians who exhibit proven leadership in their specialty field. Dr. ... four locations in South Florida : ... and Boynton Beach . Dr. Rubenstein is ...
Breaking Biology Technology:Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 2CCI’s Channel Program Study Reveals 40% of IT Vendor Channel Staff Lack Adequate Access to Program and Partner Data 3Richard Rubenstein, MD Selected As One Of South Florida's Top Doctors! 2
... control ... list for airports, TORONTO, Sept. 18 /PRNewswire-FirstCall/ - Bioscrypt ... today announced,that its V-Station MIFARE V9.50 has been approved by ... for,Access Control" Qualified Products List (QPL). Products placed on ...
... Member of Select Group of Companies, Permitted to Bid as Prime Contractor ... ... Maximum of $4 Billion in Contract Value to be Awarded under ESD, ... subsidiary today announced that ViPS has,been selected as an information technology partner by ...
... PAREXEL Consulting, a,business unit of PAREXEL International (Nasdaq: ... consultancy serving the bio/pharmaceutical and medical device,industries, announced ... (GMP) capabilities in Europe to help its global ... in areas such as,manufacturing regulations, quality, and safety. ...
Cached Biology Technology:Bioscrypt's V-Station MIFARE Placed on Transportation Security Administration's Qualified Products List 2Bioscrypt's V-Station MIFARE Placed on Transportation Security Administration's Qualified Products List 3ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS 2ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS 3Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 2Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 3Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 4Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 5Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 6
(Date:4/2/2015)... , April 2, 2015 At its 2015 ... Lake City , the American College of Medical ... new directors to its Board.  Members of the ACMG ... and for forming and advancing its policies and programs. ... profession. "It,s an eventful time in medical ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... found that the risks of a premature birth quadruple ... trimesters of pregnancy. The research was conducted by Professor ... Pharmacy and the Sainte-Justine Hospital Research Center and Master,s ... of pregnant women take prescription medication. Yet many of ...
... A team of Johns Hopkins University neuroscientists has discovered patterns ... see and understand the three-dimensional structure of objects. Computers ... the experts at object vision. (That,s why some Web sites ... human users.) It seems trivial to us to describe a ...
... Reinach, Switzerland, 26 October 2008 Arpida (SWX: ... pivotal Phase III clinical trials at the 48th ... Diseases Society of America (IDSA) 46th annual meeting ... a novel antibiotic, showed high clinical cure rates ...
Cached Biology News:How we see objects in depth: The brain's code for 3-D structure 2How we see objects in depth: The brain's code for 3-D structure 3Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections 2Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections 3
... The system consists ... (Cat. No. 17001-082) and ... 17002-080). It is complete ... promoting agents, and requires ...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
... ml Dynabeads Mouse pan B (B220), ... antibody. For the efficient positive isolation ... directly from spleen or lymph node ... on mouse B cells and lytically ...
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2...
Biology Products: